User login
Key clinical point: Myelodysplastic syndrome patients who had a slower luspatercept apparent clearance (CL/F) were more likely to achieve erythroid responses, suggesting potential as an early efficacy marker.
Major finding: Luspatercept given over a dose range of 0.125 mg/kg-1.75 mg/kg yielded linear and time-invariant pharmacokinetics when given to MDS patients with anemia subcutaneously once every 3 weeks; the odds of transfusion independence at a minimum of 8 weeks increased with time-averaged exposure and plateaued at 1.0 mg/kg-1.75 mg/kg.
Study details: The data come from a review of several studies including 260 adults with anemia caused by myelodysplastic syndromes.
Disclosures: The studies in the review were funded by Bristol Myers Squibb or Acceleron. Lead author Dr. Chen and several coauthors are employees of Bristol Myers Squibb.
Citation: Chen N et al. CPT Pharmacometrics Syst Pharmacol. 2020 June 30. doi: 10.1002/psp4.12521.
Key clinical point: Myelodysplastic syndrome patients who had a slower luspatercept apparent clearance (CL/F) were more likely to achieve erythroid responses, suggesting potential as an early efficacy marker.
Major finding: Luspatercept given over a dose range of 0.125 mg/kg-1.75 mg/kg yielded linear and time-invariant pharmacokinetics when given to MDS patients with anemia subcutaneously once every 3 weeks; the odds of transfusion independence at a minimum of 8 weeks increased with time-averaged exposure and plateaued at 1.0 mg/kg-1.75 mg/kg.
Study details: The data come from a review of several studies including 260 adults with anemia caused by myelodysplastic syndromes.
Disclosures: The studies in the review were funded by Bristol Myers Squibb or Acceleron. Lead author Dr. Chen and several coauthors are employees of Bristol Myers Squibb.
Citation: Chen N et al. CPT Pharmacometrics Syst Pharmacol. 2020 June 30. doi: 10.1002/psp4.12521.
Key clinical point: Myelodysplastic syndrome patients who had a slower luspatercept apparent clearance (CL/F) were more likely to achieve erythroid responses, suggesting potential as an early efficacy marker.
Major finding: Luspatercept given over a dose range of 0.125 mg/kg-1.75 mg/kg yielded linear and time-invariant pharmacokinetics when given to MDS patients with anemia subcutaneously once every 3 weeks; the odds of transfusion independence at a minimum of 8 weeks increased with time-averaged exposure and plateaued at 1.0 mg/kg-1.75 mg/kg.
Study details: The data come from a review of several studies including 260 adults with anemia caused by myelodysplastic syndromes.
Disclosures: The studies in the review were funded by Bristol Myers Squibb or Acceleron. Lead author Dr. Chen and several coauthors are employees of Bristol Myers Squibb.
Citation: Chen N et al. CPT Pharmacometrics Syst Pharmacol. 2020 June 30. doi: 10.1002/psp4.12521.